Digital health company ResApp Health (ASX:RAP) has announced the establishment of a COVID-19 Scientific Advisory Board (SAB).
The company said the SAB will provide scientific and clinical advice to its COVID-19 programs that are focused on delivering screening and disease management tools.
The first appointees to the SAB are four leading clinicians from the US and Australia.
Professor Elizabeth Talbot is Professor of Medicine in the Infectious Diseases and International Health Section at the Geisel School of Medicine at Dartmouth in the US.
Professor Catherine Bennett is the inaugural chair in Epidemiology and head of Deakin Epidemiology at the Institute for Health Transformation at Deakin University.
Associate Professor Mark Howard is the director of the Victorian Respiratory Support Service and Institute for Breathing and Sleep at Austin Health.
Associate Professor Paul Porter is a current ResApp scientific advisor and has been the principal investigator on several of the company's foundational clinical trials.
ResApp Health CEO and managing director Dr Tony Keating said, “We are proud to have attracted a panel of high calibre and experienced clinicians to our COVID-19 SAB. Collectively, this panel brings many years of experience in public health, epidemiology, and infectious and respiratory disease. We look forward to working with this panel of talented clinicians to optimise our research and development of tools for COVID-19.”